Darren Denjay Pan, MD, on Multiple Myeloma: Inflammatory Biomarkers and Outcomes After CAR T-Cell Therapy
2023 ASH
Darren Denjay Pan, MD, of Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, discusses his findings on risk assessment of CAR T-cell therapy for patients with multiple myeloma. Higher fibrinogen and ferritin values at baseline were associated with inferior overall survival after CAR T-cell therapy, even after controlling for tumor burden. Higher baseline absolute lymphocyte count was also associated with higher risk and grade of immune effector cell–associated neurotoxicity syndrome, an important toxicity to consider for patients receiving CAR T (Abstract 92).
The ASCO Post Staff
Ibrahim Aldoss, MD, of City of Hope National Medical Center, discusses phase II safety and efficacy results from the Augment-101 study. This trial showed that patients with heavily pretreated, relapsed or refractory KMT2-rearranged acute leukemia benefited from monotherapy with the menin-KMT2A inhibitor revumenib, with high overall response rates and undetectable measurable residual disease (Abstract LBA-5).
The ASCO Post Staff
Sanjal H. Desai, MBBS, of the University of Minnesota, discusses results from a multicenter cohort, which shows that, for transplant-eligible patients with relapsed or refractory classical Hodgkin lymphoma, PD-1–based salvage therapy at any point before transplantation is associated with improved progression-free survival, compared with brentuximab vedotin or chemotherapy-based salvage regimens (Abstract 182).
The ASCO Post Staff
Mazyar Shadman, MD, MPH, of the University of Washington, discusses new data suggesting that in patients with relapsed large B-cell lymphoma who achieve a complete response, treatment with autologous transplantation may be associated with a lower relapse rate and improved progression-free survival compared with CAR T-cell therapy, including those with early treatment failure (Abstract 781).
The ASCO Post Staff
Mikkael A. Sekeres, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, reviews key abstracts from ASH 2023 on treatment of myelofibrosis, chronic lymphocytic leukemia, large B-cell lymphoma, and acute myeloid leukemia (Abstracts 620, 631, 781, 425).
The ASCO Post Staff
Sarah C. Rutherford, MD, of Weill Cornell Medicine, discusses findings of the SWOG S1826 study, which showed nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) improved progression-free and event-free survival and seemed to be better tolerated than brentuximab vedotin plus AVD in patients aged 60 and older with advanced-stage Hodgkin lymphoma (Abstract 181).
